Alternatives to Incruse Ellipta If You Can't Fill Your Prescription

If you can't fill your Incruse Ellipta prescription — whether due to stock availability at local pharmacies, insurance issues, or cost barriers — you have options. Incruse Ellipta (umeclidinium) belongs to a class of COPD medications called long-acting muscarinic antagonists (LAMAs). Several other LAMAs are FDA-approved and may be available when Incruse Ellipta is not. Here's a clear comparison of your alternatives.

Important: Never switch your maintenance inhaler without talking to your prescriber first. The medications described here are similar but not identical to Incruse Ellipta, and your doctor will help determine whether a switch is appropriate for your situation.

Why All LAMA Alternatives Work Similarly to Incruse Ellipta

Incruse Ellipta's active ingredient, umeclidinium, blocks muscarinic receptors (M1, M2, and M3) in the airway smooth muscle. This prevents acetylcholine from binding to these receptors, which keeps the bronchial muscles relaxed and the airways open for 24 hours. All LAMA medications work via this same pathway — they differ primarily in their specific receptor binding profiles, inhaler devices, dosing frequency, and available forms.

Tiotropium (Spiriva HandiHaler and Spiriva Respimat)

Tiotropium is the most widely prescribed LAMA in the United States and the most studied long-acting anticholinergic for COPD. It is available in two devices: the HandiHaler (18 mcg dry powder capsule once daily) and the Respimat inhaler (2.5 mcg soft mist, 2 inhalations once daily). Spiriva has a longer market history than Incruse Ellipta and is generally widely stocked at most pharmacies.

In head-to-head clinical trials, umeclidinium demonstrated a statistically significant improvement in FEV1 over tiotropium at 12 weeks (approximately 53–59 mL difference). However, both medications produce clinically meaningful bronchodilation and are considered equivalent first-line options for COPD maintenance therapy. Tiotropium may be preferred if Incruse Ellipta is unavailable, if cost is a concern, or if a patient is more comfortable with an established device.

Availability: Widely stocked at most chain and independent pharmacies.

Price: Brand-name Spiriva is similarly priced to Incruse Ellipta. Spiriva Respimat has a GSK patient assistance program.

Aclidinium (Tudorza Pressair)

Aclidinium bromide (Tudorza Pressair) is a twice-daily LAMA available as a dry powder inhaler (400 mcg per actuation). It is FDA-approved for maintenance treatment of COPD and has a similar side effect profile to other LAMAs — nasopharyngitis, cough, and the anticholinergic risks of urinary retention and glaucoma worsening. Because it is dosed twice daily rather than once daily, some patients may find adherence more challenging than with once-daily options.

Availability: Stocked at most pharmacies, though less commonly than tiotropium.

Price: Generally comparable to other brand-name LAMAs; check GoodRx for current coupon pricing.

Revefenacin (Yupelri)

Revefenacin (Yupelri) is a once-daily LAMA delivered via nebulizer rather than a handheld inhaler. It is FDA-approved for maintenance treatment of COPD and is particularly useful for patients who have difficulty using a dry powder inhaler — including those with severe COPD and very limited inspiratory flow, or those with dexterity or coordination challenges. Each dose is 175 mcg nebulized once daily.

Availability: Available at most pharmacies, including specialty and mail-order. Requires a nebulizer machine.

Price: Brand-name pricing similar to other LAMAs; may be covered on formularies that don't cover inhaled LAMAs.

Anoro Ellipta (Umeclidinium + Vilanterol)

If your doctor was previously considering adding a long-acting beta-agonist (LABA) to your regimen, Anoro Ellipta (umeclidinium 62.5 mcg + vilanterol 25 mcg) is a once-daily combination LAMA/LABA inhaler that contains the same umeclidinium found in Incruse Ellipta. It's also made by GSK and uses the same Ellipta inhaler device. Because combination inhalers have higher patient volumes, Anoro Ellipta may be more reliably stocked at pharmacies than Incruse Ellipta monotherapy.

Note: Stepping up to Anoro should only be done under your doctor's guidance, as it adds a second drug class.

Trelegy Ellipta (Triple Therapy)

For patients with more severe COPD, frequent exacerbations, or persistent symptoms despite LAMA monotherapy, Trelegy Ellipta (fluticasone furoate 100 mcg + umeclidinium 62.5 mcg + vilanterol 25 mcg) is a once-daily triple therapy inhaler. It combines an inhaled corticosteroid (ICS) with a LAMA and a LABA. Like Anoro Ellipta, it uses the same Ellipta device and contains the same umeclidinium. If your pulmonologist was already considering stepping up therapy, this is an option worth discussing — but it requires clinical justification.

Summary Comparison Table

Here's a quick overview of the alternatives discussed above:

• Tiotropium (Spiriva): LAMA, once daily, widely available, dry powder or soft mist inhaler.
• Aclidinium (Tudorza Pressair): LAMA, twice daily, dry powder inhaler.
• Revefenacin (Yupelri): LAMA, once daily, nebulized solution.
• Anoro Ellipta (umeclidinium + vilanterol): LAMA/LABA combination, once daily, Ellipta device.
• Trelegy Ellipta (fluticasone/umeclidinium/vilanterol): Triple therapy ICS/LAMA/LABA, once daily, Ellipta device.

How to Have the Conversation With Your Doctor

When you contact your provider, be specific. Tell them: "I've been unable to fill my Incruse Ellipta prescription at local pharmacies. Can you recommend an alternative LAMA, or can you help me locate a pharmacy that has it?" It also helps to have already tried basic availability tools like medfinder before your appointment so your doctor knows you've exhausted other options.